FierceBiotech

Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment

THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women ...
Yahoo Finance

Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Combined sales of Prolia® and Xgeva® (denosumab) which are used to treat bone diseases were nearly $5.3 billion in 2021 Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development ...
Yahoo Finance

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a ...
FiercePharma

Amgen's Prolia wins new uses, performs in study

Meanwhile, Prolia scored in long-term results from an extended trial. Post-menopausal women treated with Prolia for up to 8 years saw their bone mineral density increase by 16.8% on average in the ...
Monthly Prescribing Reference

Long-Term BMD Gain With Prolia Shown in 10-Year Study Data

PROLIA (denosumab) 60mg subcutaneous injection by Amgen Amgen announced results from a 7-year, single-arm, open-label extension of the 3-year randomized, double-blind, placebo-controlled, multi-center ...
Hosted on MSN

Amgen’s Prolia® Study: A New Frontier in Osteoporosis Treatment

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Nasdaq

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a ...
FiercePharma

Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment | Fierce Pharma

THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women ...
Seeking Alpha

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

REYKJAVIK, Iceland, July 02, 2024 (GLOBE NEWSWIRE) -- Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today ...
Pharmabiz

Prolia phase II extension study showed continued increase in bone mineral density over 8 years of treatment

Amgen discovers, develops, manufactures and delivers innovative human therapeutics, announced new long-term data showing that Prolia (denosumab) treatment for up to eight years in post-menopausal ...
Nasdaq

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability ...